JERSEY CITY, N.J., Oct. 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), a biotechnology company delivering innovative
Each year in the U.S., at least 2 million people are infected with antimicrobial-resistant pathogens, and at least 23,000 people die as a result. The AMR Challenge, which was launched at the United Nations (UN) General Assembly in September 2018, tasks governments, private industries, and non-governmental organizations worldwide to make formal commitments that will further address the growing problem of antimicrobial resistance through September 2019. SCYNEXIS has committed to initiate studies of its lead agent, Ibrexafungerp (formerly SCY-078), in the treatment of patients with invasive aspergillosis as well as patients with fungal infections that are resistant to current therapies, including patients with Candida auris. To learn more about or to join the AMR Challenge, visit: https://www.cdc.gov/drugresistance/intl-activities/amr-challenge.html
In addition to the AMR Challenge, SCYNEXIS recognizes and encourages participation in the CDC's second annual Fungal Disease Awareness Week, occurring October 1-5, 2018. The week aims to raise awareness of fungal infections and the need to detect them early on in a patient's illness. If left untreated, or if appropriate treatment is delayed, patients can suffer serious morbidity and even death.
To learn more about Fungal Disease Awareness Week and how you can help spread the word, visit: https://www.cdc.gov/fungal/awareness-week.html
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Forward Looking StatementStatements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS's reliance on third parties to conduct SCYNEXIS's clinical studies. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
Investor RelationsNatalie WildenradtArgot PartnersTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-supports-amr-challenge-and-fungal-disease-awareness-week-300721792.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!